Zeiss and Ilmenau University open new research lab

Article

Carl Zeiss Meditec AG and the Ilmenau University, Germany, have formed a partnership to open a new ophthalmic laboratory at the Institut für Biomedizinische Technik und Informatik in Germany.

Carl Zeiss Meditec AG and the Ilmenau University, Germany, have formed a partnership to open a new ophthalmic laboratory at the Institut für Biomedizinische Technik und Informatik in Germany.

The laboratory is distinguished by housing the latest in diagnostic systems, particularly those used for the examination of the posterior segment. There are to be three main areas of research: to combine previously independent examination methods, to develop more powerful systems with easily interpretable diagnostic data for the early detection of eye disorders and to integrate diagnosis with therapy in a comprehensive patient-orientated treatment approach.

The main aim of these projects is to develop early diagnosis and improved monitoring of eye disorders such as glaucoma, diabetic retinopathy, age-related macular degeneration and arterial/venous occlusion.

The laboratory was made possible by "research and development infrastructure" support from the Thuringian Ministry of Education and Arts.

Elsewhere, Dr Michael Kaschke, Director of Carl Zeiss AG and Chairman of the Supervisory Board of Carl Zeiss Meditec AG, has also announced the opening of the first training centre for ophthalmology at the Cicendo Hospital in Bandung, Indonesia, together with Dr Gullapalli N. Rao, President of IAPB (International Agency for the Prevention of Blindness) and representatives of the Indonesian government.

Carl Zeiss is supporting the foundation of the training centre with a donation of $200,000, which will be used for training staff and equipping the centre. The company also donated several systems for diagnosis, treatment and aftercare, including slit lamps, treatment lasers and a surgical microscope.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.